Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc. (XENE) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · XENE · as of Sep 30, 2025
Ownership Breakdown
230
Institutional Holders
▲ 17 vs Q2
$3.39B
Total Inst. Value
▲ $783.00M vs Q2
78.95M
Shares Outstanding
freeFloat 99.34%
84.32M
13F Shares Held
▲ 1.19M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
XENE largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
FMR LLC pharmaceutical preparations | 8.92M | 11.30% | 11.30% | $358.09B | Nov 13, 2025 | ▲ 34.5K |
AVORO CAPITAL ADVISORS LLC pharmaceutical preparations | 5.40M | 6.84% | 6.84% | $216.81B | Nov 14, 2025 | — held |
BLACKROCK, INC. pharmaceutical preparations | 4.77M | 6.04% | 6.04% | $191.55B | Nov 12, 2025 | ▼ 594.4K |
DRIEHAUS CAPITAL MANAGEMENT LLC pharmaceutical preparations | 4.17M | 5.28% | 5.28% | $167.39B | Nov 14, 2025 | ▼ 166.5K |
JANUS HENDERSON GROUP PLC pharmaceutical preparations | 3.94M | 5.00% | 5.00% | $158.31B | Nov 14, 2025 | ▲ 366.1K |
WELLINGTON MANAGEMENT GROUP LLP pharmaceutical preparations | 3.61M | 4.57% | 4.57% | $144.94B | Nov 14, 2025 | ▲ 1.44M |
BRAIDWELL LP pharmaceutical preparations | 3.61M | 4.57% | 4.57% | $144.74B | Nov 14, 2025 | — held |
CAPITAL INTERNATIONAL INVESTORS pharmaceutical preparations | 3.18M | 4.03% | 4.03% | $127.74B | Nov 13, 2025 | ▼ 56 |
COMMODORE CAPITAL LP pharmaceutical preparations | 2.70M | 3.42% | 3.42% | $108.41B | Nov 14, 2025 | ▼ 325.0K |
POLAR CAPITAL HOLDINGS PLC pharmaceutical preparations | 2.55M | 3.23% | 3.23% | $102.25B | Nov 14, 2025 | ▼ 156.5K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
23
Increased
+5.72M shares1
New Positions
first time holders19
Decreased
−4.10M shares0
Sold Out
fully exitedNet shares change (top 50)
+1.62M
+5.72M / −4.10M
Net new holders
+5
1 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
XENE insider trading · insider activity
Source: SEC Form 4
22
Buy transactions
10
Sell transactions
2.20
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
PATOU GARY director | Jun 3, 2026 | Award | 10,507 | $53.46 | $561.7K | 10.5K | Form 4 ↗ |
PATOU GARY director | Jun 3, 2026 | Award | 1,593 | — | — | 1.6K | Form 4 ↗ |
Machado Patrick director | Jun 3, 2026 | Award | 10,507 | $53.46 | $561.7K | 10.5K | Form 4 ↗ |
Machado Patrick director | Jun 3, 2026 | Award | 1,593 | — | — | 1.6K | Form 4 ↗ |
Gover Justin D. director | Jun 3, 2026 | Award | 10,507 | $53.46 | $561.7K | 10.5K | Form 4 ↗ |
Gover Justin D. director | Jun 3, 2026 | Award | 1,593 | — | — | 1.6K | Form 4 ↗ |
GAROFALO ELIZABETH A. director | Jun 3, 2026 | Award | 10,507 | $53.46 | $561.7K | 10.5K | Form 4 ↗ |
GAROFALO ELIZABETH A. director | Jun 3, 2026 | Award | 1,593 | — | — | 1.6K | Form 4 ↗ |
GANNON STEVEN director | Jun 1, 2026 | Tax Withhold | 1,416 | $53.41 | $75.6K | 11.9K | Form 4 ↗ |
GANNON STEVEN director | Jun 3, 2026 | Award | 10,507 | $53.46 | $561.7K | 10.5K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Xenon Pharmaceuticals Inc. (XENE) is primarily owned by institutional investors, who hold approximately 100.0% of total shares outstanding. Company insiders own approximately 0.66%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Xenon Pharmaceuticals Inc. is FMR LLC, holding approximately 8.92 million shares — equal to 11.30% of outstanding shares — as of September 30, 2025.
A total of 230 institutional investors currently hold XENE stock, with a combined institutional value of approximately $3.39 billion as of the most recent 13F filing period.
Frequently asked questions
XENE ownershipXenon Pharmaceuticals Inc. (XENE) is primarily owned by institutional investors, who hold approximately 100.0% of shares. The largest shareholder is FMR LLC with a 11.30% stake. Company insiders hold 0.66%. Data sourced from SEC Form 13F as of September 30, 2025.